DOCSLIB.ORG

Recent Advances in Doping Analysis (27)

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Recent Advances in Doping Analysis (27) M. THEVIS H. GEYER U. MARECK (EDITORS) RECENT ADVANCES IN DOPING ANALYSIS (27) Proceedings of the Manfred Donike Workshop 37th Cologne Workshop on Dope Analysis 17th to 22nd February 2019 SPORTVERLAG Strauß - Hellenthal 2019 Bibliografische Information Der Deutschen Nationalbibliothek Die Deutsche Nationalbibliothek verzeichnet diese Publikation in der Deutschen Nationalbibliografie; detaillierte bibliografische Daten sind im Internet über <http://dnb.d‐nb.de> abrufbar. Thevis, Mario; Geyer, Hans; Mareck, Ute (Eds.) Recent Advances in Doping Analysis (27). Proceedings of the Manfred Donike Workshop, 37th Cologne Workshop on Dope Analysis, 17th to 22nd February 2019 / [MDI e.V.] – 2019 Sportverlag Strauß. ISBN 978‐3‐86884‐045‐2 ©SPORTVERLAG Strauß Neuhaus 12 – 53940 Hellenthal Tel. +49 (0)2448/2470040 – Fax +49 (0)2448/9195610 E‐mail: info@sportverlag‐strauss.de www.sportverlag‐strauss.de Satz: Autorensatz RECENT ADVANCES IN DOPING ANALYSIS (27) 2 ISBN 978-3-86884-045-2 MANFRED DONIKE WORKSHOP 2019 TABLE OF CONTENTS LECTURES PAGE Perspective Article: Biasini GM, Botrè F, de la Torre X, Donati F: Electrical brain stimulation: the rise of a new doping method? ................................................ 11‐16 POSTER PRESENTATIONS Piper T, Thevis M: Do urinary concentrations of dimethyl sulfoxide and its metabolite dimethyl sulfone indicate topical administrations of doping agents? ..................................................................... 17‐20 Muñoz G , Baltazar‐Martins JG , Plata MDM , Muñoz‐Guerra J , Carreras D , del Coso J: Prevalence of use of tramadol in conjunction with other non‐ prohibited stimulants ............. 21‐24 Martin L, Martin J, Hoang O, Collot D, Audran M, Marchand A: Detection of rEPOs in plasma from ABP blood samples: impact of freeze‐thaw cycle and hemolysis ................................................................................................................................ 25‐29 Romberg S, Kempkes R, Thevis M: Athlete Biological Passport in Practice: Computer Assisted Evaluation of Sysmex Measurements at the Analysis Site .............................................................................................. 30‐34 Fußhöller G, Geyer H, Schänzer W, Thevis M: Bacterial activities in urine samples: Formation of metandienone and 6β‐hydroxy‐ metandienone from the internal standard methyltestosterone – a case study ........................ 35‐38 Rodriguez Fernandez A, Martinez Brito D, Correa Vidal T, Lopez Castillo D, Montes de Oca Porto R: Evaluation of the steroid profile in Latin‐American population of male football players ......... 39‐44 Iannone M, di Murro V, de la Torre X, Botrè F: Effects of non‐banned and non‐monitored substances ‐ synthetic isoflavones, resveratrol and polydatin ‐ on the parameters of the urinary steroid profile ........................... 45‐49 Comunità F, Botrè F, Grippo D, Montesi G, de la Torre X, Mazzarino M: Azole antifungals and their effect on the urinary steroid profile: a dose response relationship study .......................................................................................................................... 50‐53 RECENT ADVANCES IN DOPING ANALYSIS (27) 3 ISBN 978-3-86884-045-2 PAGE Oliveira FA, Oliveira FAG, Labanca BDJ, Padilha MC, Pereira HMG: Report of four months experiencing the 2018 Technical Document for endogenous anabolic androgenic steroids in LBCD ......................................................................................... 54‐57 Masquelier M, Andersson A, Ericsson M: Confirmation of oxandrolone metabolites or the story of a false ”false positive” ................... 58‐61 Fußhöller G, Guddat S, Schänzer W, Geyer H, Thevis M: Testolactone – Derivatisation Artifact due to the Incorporation of an Ethylmercapto Group ............................................................................................................................................ 62‐65 Shiomura S, Kageyama S, Okano M: Urinary steroid profiles and carbon isotope ratios after administration of testosterone gel in Japanese subjects ............................................................................................................... 66‐70 Jardines D, Curcio D, Colamonici C, Botrè F, de la Torre X: Inter‐individual behavior of the endogenous reference compounds ........................................ 71‐74 Ericsson M, Thörngren J, Hopcraft O: A new sample preparation procedure for GC‐C‐IRMS analysis using mixed mode SPE and MS/MS detection for HPLC‐fractionation ............................................................................ 75‐80 Ndlovu F , Van der Merwe M , Goebel C , Grainger J: Development and validation of a method for the detection of small peptides in doping control .............................................................................................................................. 81‐86 Radu M , Berghes B , Toboc A: Development and validation of a LC‐HRMS method for the detection of small peptides in human urine .............................................................................................................. 87‐90 Pettersson‐Bohlin K, von Walden J, Ericsson M, Thörngren J: Confirmation of derivatized methylhexanamine and its isomers using Q‐exactive ................. 91‐93 Olgaz Bingöl S, Onol S, Aytekin S, Basaran AA: Differentiation of Modafinil and Dimenhydrinate by UPLC‐ESI‐MS/MS in Doping Analysis ......................................................................................................................................... 94‐97 Krug O , Thomas A , Walpurgis K , Piper T , Geyer H , Thevis M: Black market products suspected to contain doping relevant ingredients ‐ annual report for 2018 ............................................................................................................................ 98‐102 PRESENTATIONS ABSTRACTS ‐ LECTURES Garzinsky AM , Walpurgis K , Krug O , Thevis M: Does saliva contribute to exhaled breath samples collected by means of an electret membrane? ...................................................................................................................................... 103 RECENT ADVANCES IN DOPING ANALYSIS (27) 4 ISBN 978-3-86884-045-2 PAGE Van Wagoner R, Miller G, Husk J, Bruno B, Eichner D: Investigating oral fluid and exhaled breath as alternative matrices for anti‐doping testing: a collaborative study with minor league baseball and the partnership for clean competition ............................................................................................................................. 104 Pereira HM, Sardela V, Matos R, Prado E, Gomes G, Lima de Sá C, Anselmo C, Nunes I, Ramalho G, Padilha M, Vanini G, Oliveira MA, Oliveira A, Amaral L, Canuto C, Siqueira D, Ambrósio J, de Aquino Neto FR: Zebrafish water tank model: scale down, study pipeline and reference collections .................... 105 Coll Camenforte S , Matabosch Gerones X , Llorente Onaindia J , Pérez Mañá C , Monfort Mercader N, Monfort Faure J , Ventura Alemany R: Elimination profile of triamcinolone hexacetonide and its metabolites in human urine and plasma after a single intra‐articular administration ................................................................ 106 Reichel C, Fröschl H, Gmeiner G: Establishing doping‐related reference distributions for cobalt in human urine .................... 107‐108 Lange T , Walpurgis K , Thomas A , Geyer H , Thevis M: Development of two complementary LC‐HRMS methods for analyzing Sotatercept in dried blood spots for doping controls ............................................................................................. 109 Thomas A, Thevis M: Identification of metabolites of peptide‐derived drugs using skin tissue microsomes and Isotope‐labeled Reporter Ion Detection strategy ................................................................... 110 Piper T, Fusshöller G, Schänzer W, Thevis M: Investigations into the in vivo metabolism of Methylstenbolone .......................................... 111‐112 Cavalcanti G, Gujar A, Pereira H, Padilha M: Advanced Electron Ionization source (AEI source) : Improving the reliability of confirmation methods in sports drug testing ................................................................................. 113 Polet M, Van Gansbeke W, Albertsdóttir AD, Coppieters G, Deventer K, Van Eenoo P: Analysis of non‐hydrolyzed sulfated steroids by gas chromatography mass spectrometry ......... 114 Martinez‐Brito D, de la Torre X, Botrè F: 7‐Keto‐DHEA: metabolite or precursor? Potential pitfalls in interpreting the analytical results and WADA list ...................................................................................................................... 115 Mazzarino M, Martellone L, Comunità F, de la Torre X, Botrè F: Evaluation of the efficacy of the protocols used in the anti‐doping tests to reveal the presence of 5α‐reductase inhibitors ............................................................................................... 116 Alechaga E, Esquivel A, Monfort N, Ventura R: Potential of endogenous steroid sulfate metabolites as markers of intramuscular administration of testosterone in Caucasian and Asian population .............................................. 117 Miller G, Bruno B, Eichner D, Thevis M: Using pigs as an in vivo metabolic model for performance‐enhancing drugs ............................... 118 RECENT ADVANCES IN DOPING ANALYSIS (27) 5 ISBN 978-3-86884-045-2 PAGE Ponzetto F, Nicoli R, Kuuranne T, Saugy M, Boccard
Load more

Recommended publications
  • Modafinil Tablets
    PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION PrAURO-MODAFINIL Modafinil Tablets 100 mg House Standard Central Nervous System Stimulant Auro Pharma Inc. 3700 Steeles Avenue West, Suite # 402 Date of Revision: Woodbridge, ON, L4L 8K8, August 8, 2019. CANADA Submission Control Number: 230314 Page 1 of 41 Table of Contents PART I: HEALTH PROFESSIONAL INFORMATION ......................................................... 3 SUMMARY PRODUCT INFORMATION .................................................................... 3 INDICATIONS AND CLINICAL USE .......................................................................... 3 CONTRAINDICATIONS ............................................................................................... 4 WARNINGS AND PRECAUTIONS .............................................................................. 4 ADVERSE REACTIONS .............................................................................................. 12 DRUG INTERACTIONS .............................................................................................. 16 DOSAGE AND ADMINISTRATION .......................................................................... 19 OVERDOSAGE ............................................................................................................ 21 ACTION AND CLINICAL PHARMACOLOGY ........................................................ 21 STORAGE AND STABILITY ...................................................................................... 23 DOSAGE FORMS, COMPOSITION AND PACKAGING
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 De Juan Et Al
    US 200601 10428A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 de Juan et al. (43) Pub. Date: May 25, 2006 (54) METHODS AND DEVICES FOR THE Publication Classification TREATMENT OF OCULAR CONDITIONS (51) Int. Cl. (76) Inventors: Eugene de Juan, LaCanada, CA (US); A6F 2/00 (2006.01) Signe E. Varner, Los Angeles, CA (52) U.S. Cl. .............................................................. 424/427 (US); Laurie R. Lawin, New Brighton, MN (US) (57) ABSTRACT Correspondence Address: Featured is a method for instilling one or more bioactive SCOTT PRIBNOW agents into ocular tissue within an eye of a patient for the Kagan Binder, PLLC treatment of an ocular condition, the method comprising Suite 200 concurrently using at least two of the following bioactive 221 Main Street North agent delivery methods (A)-(C): Stillwater, MN 55082 (US) (A) implanting a Sustained release delivery device com (21) Appl. No.: 11/175,850 prising one or more bioactive agents in a posterior region of the eye so that it delivers the one or more (22) Filed: Jul. 5, 2005 bioactive agents into the vitreous humor of the eye; (B) instilling (e.g., injecting or implanting) one or more Related U.S. Application Data bioactive agents Subretinally; and (60) Provisional application No. 60/585,236, filed on Jul. (C) instilling (e.g., injecting or delivering by ocular ion 2, 2004. Provisional application No. 60/669,701, filed tophoresis) one or more bioactive agents into the Vit on Apr. 8, 2005. reous humor of the eye. Patent Application Publication May 25, 2006 Sheet 1 of 22 US 2006/0110428A1 R 2 2 C.6 Fig.
    [Show full text]
  • These Highlights Do Not Include All the Information Needed to Use PROVIGIL Safely and Effectively
    PROVIGIL- modafinil tablet Bryant Ranch Prepack ---------- HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use PROVIGIL safely and effectively. See full prescribing information for PROVIGIL. PROVIGIL® (modafinil) tablets, for oral use, C-IV Initial U.S. Approval: 1998 INDICATIONS AND USAGE PROVIGIL is indicated to improve wakefulness in adult patients with excessive sleepiness associated with narcolepsy, obstructive sleep apnea (OSA), or shift work disorder (SWD). (1) Limitations of Use In OSA, PROVIGIL is indicated to treat excessive sleepiness and not as treatment for the underlying obstruction. DOSAGE AND ADMINISTRATION The recommended dosage of PROVIGIL for each indication is as follows: • Narcolepsy or OSA: 200 mg once a day in the morning. (2.1) • SWD: 200 mg once a day, taken approximately one hour prior to start of the work shift. (2.2) • Severe Hepatic Impairment: reduce dose to half the recommended dose. (2.3, 12.3) • Geriatric Patients: consider lower dose. (2.4, 12.3) DOSAGE FORMS AND STRENGTHS Tablets: 100 mg and 200 mg. (3) CONTRAINDICATIONS PROVIGIL is contraindicated in patients with known hypersensitivity to modafinil or armodafinil. (4) WARNINGS AND PRECAUTIONS • Serious Rash, including Stevens-Johnson Syndrome: Discontinue PROVIGIL at the first sign of rash, unless the rash is clearly not drug-related. (5.1) • Angioedema and Anaphylaxis Reactions: If suspected, discontinue PROVIGIL. (5.2) • Multi-organ Hypersensitivity Reactions: If suspected, discontinue PROVIGIL. (5.3) • Persistent Sleepiness: Assess patients frequently for degree of sleepiness and, if appropriate, advise patients to avoid driving or engaging in any other potentially dangerous activity. (5.4) • Psychiatric Symptoms: Use caution in patients with a history of psychosis, depression, or mania.
    [Show full text]
  • Customs Tariff - Schedule
    CUSTOMS TARIFF - SCHEDULE 99 - i Chapter 99 SPECIAL CLASSIFICATION PROVISIONS - COMMERCIAL Notes. 1. The provisions of this Chapter are not subject to the rule of specificity in General Interpretative Rule 3 (a). 2. Goods which may be classified under the provisions of Chapter 99, if also eligible for classification under the provisions of Chapter 98, shall be classified in Chapter 98. 3. Goods may be classified under a tariff item in this Chapter and be entitled to the Most-Favoured-Nation Tariff or a preferential tariff rate of customs duty under this Chapter that applies to those goods according to the tariff treatment applicable to their country of origin only after classification under a tariff item in Chapters 1 to 97 has been determined and the conditions of any Chapter 99 provision and any applicable regulations or orders in relation thereto have been met. 4. The words and expressions used in this Chapter have the same meaning as in Chapters 1 to 97. Issued January 1, 2020 99 - 1 CUSTOMS TARIFF - SCHEDULE Tariff Unit of MFN Applicable SS Description of Goods Item Meas. Tariff Preferential Tariffs 9901.00.00 Articles and materials for use in the manufacture or repair of the Free CCCT, LDCT, GPT, UST, following to be employed in commercial fishing or the commercial MT, MUST, CIAT, CT, harvesting of marine plants: CRT, IT, NT, SLT, PT, COLT, JT, PAT, HNT, Artificial bait; KRT, CEUT, UAT, CPTPT: Free Carapace measures; Cordage, fishing lines (including marlines), rope and twine, of a circumference not exceeding 38 mm; Devices for keeping nets open; Fish hooks; Fishing nets and netting; Jiggers; Line floats; Lobster traps; Lures; Marker buoys of any material excluding wood; Net floats; Scallop drag nets; Spat collectors and collector holders; Swivels.
    [Show full text]
  • Download (PDF 277.63
    PROJECT REVIEW “Characterization of the main metabolites of 17-methylstenblone and 17 methylmethenolone produced by human hepatocytes and liver fractions” Prof C. Ayotte, (INRS-Institut Armand-Frappier, Canada) New steroids openly appear on the market in products labelled with a rather confusing nomenclature. Once characterized, pharmaceutical grade products not being available, knowledge of the biotransformation pathways essential to an efficient detection of utilization by athletes is difficult to gain since administration to human volunteers should be restricted to the minimum. The alternative is a reliable in vitro model. Human hepatocytes, fresh or cryopreserved are now available commercially. We have successfully produced and identified phase I metabolites from incubations of human hepatocytes with different steroids, such as 17-methyldrostanolone and desoxymethyltestosterone (DMT). The aim of this project is to produce in vitro from human hepatocytes and liver fractions the metabolites of two steroids, the 17-methylated derivatives of stenbolone and its isomer methenolone. The principal metabolites will be synthesized and characterized by NMR and mass spectrometry. The characterization of metabolites will enable the identification of markers of utilization to be incorporated in routine testing methods. The approach for the chemical synthesis of metabolites will be shared with NMI insuring the distribution to other doping control laboratories. Improving the knowledge of steroid biotransformation is a further benefit from these studies. Characterization of 17-Methylstenbolone and 17-Methylmethenolone and Identification of Metabolites Produced by Human Hepatocytes and Liver Fractions WADA Project no. 11A16CA Christiane Ayotte, Philippe Räss, Alexandre Sylvestre, INRS-Institut Armand-Frappier Summary We have synthesized and characterized two designer steroids, 17α-methylmethenolone and 17α- methylstenbolone; the latter is proposed on the internet and two groups have reported different and contradictory results.
    [Show full text]
  • Fluorophosphonium Chemistry: Applying Strategies Learned from Boron to Phosphorus
    Fluorophosphonium Chemistry: Applying Strategies Learned from Boron to Phosphorus by Shawn William Postle A thesis submitted in conformity with the requirements for the degree of Doctor of Philosophy Department of Chemistry University of Toronto Fluorophosphonium Chemistry: Applying Strategies Learned from Boron to Phosphorus Shawn William Postle Doctor of Philosophy Department of Chemistry University of Toronto Abstract Since the inception of frustrated Lewis pair chemistry, interest in main group catalysts has undergone a resurgence. Central to the success of many main group systems is the pentafluorophenyl substituent, which provides both chemical stability and electrophilicity to the catalyst. Pentafluorophenyl substituents have been used with boranes, alanes, and recently in fluorophosphonium cations. This thesis investigates a range of related aryl substituents applied to fluorophosphonium chemistry to elicit new catalyst properties. Nitrene insertion into the bonds of borane substituents, including perfluorophenyl groups, was used to tune the electrophilicity of main group systems. Sterically demanding pentachlorophenyl substituents were used to add protection to sensitive fluorophosphonium catalysts. Perfluorobiphenyl groups were used to generate more electrophilic fluorophosphonium catalysts. Binaphthyl substituents were employed to create chiral fluorophosphonium cations. ii This work is dedicated in memory of my grandpa, William Kerr, for instilling in me a genuine curiosity of the world. iii Acknowledgements First and foremost, I would like to thank Prof. Doug Stephan for providing me with this experience. By providing me with the freedom to pursue my own interests and offering insightful guidance whenever it was sought, you have helped me become a better chemist. I would like to thank my committee members, Prof. Bob Morris and Prof.
    [Show full text]
  • Contribution of Mass Spectrometry for the Detection of Xenobiotics
    Contribution of mass spectrometry for the detection of xenobiotics implicated in cases of drug-facilitated crimes and the quantitation of urinary metabolites of polycyclic aromatic hydrocarbons Mohammed K.S. Shbair To cite this version: Mohammed K.S. Shbair. Contribution of mass spectrometry for the detection of xenobiotics implicated in cases of drug-facilitated crimes and the quantitation of urinary metabolites of polycyclic aromatic hydrocarbons. Human health and pathology. Université du Droit et de la Santé - Lille II, 2011. English. NNT : 2011LIL2S011. tel-00647316 HAL Id: tel-00647316 https://tel.archives-ouvertes.fr/tel-00647316 Submitted on 1 Dec 2011 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. University Lille 2 of Health and Law Doctorate School of Health and Biology Thesis for the Degree of Doctorate of Lille 2 University Discipline: TOXICOLOGY By Mohammed K.S. SHBAIR Contribution of mass spectrometry for the detection of xenobiotics implicated in cases of drug-facilitated crimes and the quantitation of urinary metabolites of polycyclic aromatic hydrocarbons Thesis defended 23rd June 2011 Members of the jury: Reviewers: Prof. Dr. Jean-Pierre GOULLÉ Prof. Dr. Christian STAUB Examiners : Prof. Dr.
    [Show full text]
  • Supporting Information a Analysed Substances
    Electronic Supplementary Material (ESI) for Analyst. This journal is © The Royal Society of Chemistry 2020 List of contents: Tab. A1 Detailed list and classification of analysed substances. Tab. A2 List of selected MS/MS parameters for the analytes. Tab. A1 Detailed list and classification of analysed substances. drug of therapeutic doping agent analytical standard substance abuse drug (WADA class)* supplier (+\-)-amphetamine ✓ ✓ S6 stimulants LGC (+\-)-methamphetamine ✓ S6 stimulants LGC (+\-)-3,4-methylenedioxymethamphetamine (MDMA) ✓ S6 stimulants LGC methylhexanamine (4-methylhexan-2-amine, DMAA) S6 stimulants Sigma cocaine ✓ ✓ S6 stimulants LGC methylphenidate ✓ ✓ S6 stimulants LGC nikethamide (N,N-diethylnicotinamide) ✓ S6 stimulants Aldrich strychnine S6 stimulants Sigma (-)-Δ9-tetrahydrocannabinol (THC) ✓ ✓ S8 cannabinoids LGC (-)-11-nor-9-carboxy-Δ9-tetrahydrocannabinol (THC-COOH) S8 cannabinoids LGC morphine ✓ ✓ S7 narcotics LGC heroin (diacetylmorphine) ✓ ✓ S7 narcotics LGC hydrocodone ✓ ✓ Cerillant® oxycodone ✓ ✓ S7 narcotics LGC (+\-)-methadone ✓ ✓ S7 narcotics Cerillant® buprenorphine ✓ ✓ S7 narcotics Cerillant® fentanyl ✓ ✓ S7 narcotics LGC ketamine ✓ ✓ LGC phencyclidine (PCP) ✓ S0 non-approved substances LGC lysergic acid diethylamide (LSD) ✓ S0 non-approved substances LGC psilocybin ✓ S0 non-approved substances Cerillant® alprazolam ✓ ✓ LGC clonazepam ✓ ✓ Cerillant® flunitrazepam ✓ ✓ LGC zolpidem ✓ ✓ LGC VETRANAL™ boldenone (Δ1-testosterone / 1-dehydrotestosterone) ✓ S1 anabolic agents (Sigma-Aldrich)
    [Show full text]
  • Vargas KEA, Et Al. Hepatotoxicity Associated with Methylstenbolone and Copyright© Vargas KEA, Et Al
    1. Medical Journal of Clinical Trials & Case Studies ISSN: 2578-4838 Hepatotoxicity Associated with Methylstenbolone and Stanozolol Abuse Vargas KEA*, Guaraná TA, Biccas BN, Agoglia LV, Carvalho ACG, Case Report Gismondi R and Esberard EBC Volume 2 Issue 5 Received Date: July 27, 2018 Department of Gastroenterology/Hepatology, Department of Clinical Medicine, and Published Date: September 03, 2018 Department of Pathology, Antônio Pedro University Hospital, Federal Fluminense DOI: 10.23880/mjccs-16000176 University, Rio de Janeiro, Brazil *Corresponding author: Vargas Karen Elizabeth Arce, Department of Gastroenterology/Hepatology, Department of Clinical Medicine, and Department of Pathology, Antônio Pedro University Hospital, Federal Fluminense University, Rio de Janeiro, Ernani do Amaral Peixoto Avenue, 935. Ap.901 / Cep.24020043, Brazil, Tel: 005521981584624; Email: [email protected] Abstract Background & Objectives: Drug hepatotoxicity is a major cause of liver disease. Many drugs are well known to induce liver damage. Some toxic products, like anabolic androgenic steroids, that are pharmaceutical preparations since they contain pharmaceutically active substance, are available as nutritional supplements. Many patients are used to consume these like dietary stuff. Methods: We introduce a case series of two patients who developed hepatic damage after the consumption of anabolic- androgenic steroids, accompanied by a detailed bibliographic research on this topic. Results: We present two young men who developed significant liver damage, both with hyperbilirubinemia pattern after consumption of anabolic-androgenic steroids. This was associated with considerable morbidity, although both recovered without liver transplantation. The two anabolic-androgenic steroids were being marketed as dietary supplements. Conclusions: Although not well controlled substances in Brazil, anabolic-androgenic steroids are cause of severe hepatotoxicity.
    [Show full text]
  • Antiparasitic Properties of Cardiovascular Agents Against Human Intravascular Parasite Schistosoma Mansoni
    pharmaceuticals Article Antiparasitic Properties of Cardiovascular Agents against Human Intravascular Parasite Schistosoma mansoni Raquel Porto 1, Ana C. Mengarda 1, Rayssa A. Cajas 1, Maria C. Salvadori 2 , Fernanda S. Teixeira 2 , Daniel D. R. Arcanjo 3 , Abolghasem Siyadatpanah 4, Maria de Lourdes Pereira 5 , Polrat Wilairatana 6,* and Josué de Moraes 1,* 1 Research Center for Neglected Diseases, Guarulhos University, Praça Tereza Cristina 229, São Paulo 07023-070, SP, Brazil; [email protected] (R.P.); [email protected] (A.C.M.); [email protected] (R.A.C.) 2 Institute of Physics, University of São Paulo, São Paulo 05508-060, SP, Brazil; [email protected] (M.C.S.); [email protected] (F.S.T.) 3 Department of Biophysics and Physiology, Federal University of Piaui, Teresina 64049-550, PI, Brazil; [email protected] 4 Ferdows School of Paramedical and Health, Birjand University of Medical Sciences, Birjand 9717853577, Iran; [email protected] 5 CICECO-Aveiro Institute of Materials & Department of Medical Sciences, University of Aveiro, 3810-193 Aveiro, Portugal; [email protected] 6 Department of Clinical Tropical Medicine, Faculty of Tropical Medicine, Mahidol University, Bangkok 10400, Thailand * Correspondence: [email protected] (P.W.); [email protected] (J.d.M.) Citation: Porto, R.; Mengarda, A.C.; Abstract: The intravascular parasitic worm Schistosoma mansoni is a causative agent of schistosomiasis, Cajas, R.A.; Salvadori, M.C.; Teixeira, a disease of great global public health significance. Praziquantel is the only drug available to F.S.; Arcanjo, D.D.R.; Siyadatpanah, treat schistosomiasis and there is an urgent demand for new anthelmintic agents.
    [Show full text]
  • Identification of Designer Drugs Using Gas Chromatography High-Resolution Mass Spectrometry and a Soft-Ionization Source
    Journal of Forensic Science & Criminology Volume 1 | Issue 3 ISSN: 2348-9804 Research Article Open Access Identification of Designer Drugs using Gas Chromatography High-Resolution Mass Spectrometry and A Soft-Ionization Source Lopez-Avila V* Agilent Technologies, USA *Corresponding author: Lopez-Avila V, Agilent Technologies, Santa Clara, CA 95051, USA, Fax: (408) 553- 3677, Tel: (408) 553-2709, E-mail: [email protected] Citation: Lopez-Avila V (2013) Identification of Designer Drugs using Gas Chromatography High-Resolution Mass Spectrometry and a Soft-Ionization Source. J Forensic Sci Criminol 1(3): 301. doi: 10.15744/2348- 9804.1.301 Received Date: September 27, 2013 Accepted Date: December 11, 2013 Published Date: December 16, 2013 Abstract A small set of amphetamines has been analyzed by gas chromatography (GC) high-resolution time-of-flight mass spectrometry (TOFMS) using a microplasma photoionization (MPPI) soft-ionization source. This plasma-based, wavelength selectable ionization source enables ionization of the test compounds and their corresponding derivatives at ~8-12 eV that is a softer alternative to electron ionization at 70 eV. Three plasma gases were used in this study: Xe plasma that emits photons at resonance lines of 9.57 eV and 8.44 eV; Kr plasma at 10.63 eV and 10.02 eV, and Ar plasma at 11.82 eV and 11.61 eV. Derivatization of the test compounds with trifluoroacetic anhydride and α-methoxy-α-(trifluoromethyl)-phenylacetyl pyrazole was evaluated because the MPPI mass spectra of the underivatized amphetamines yield primarily iminium ions, which make the identification of the test compounds by GC-TOFMS inconclusive.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 9.447,114 B2 Chenard Et Al
    USOO94471.14B2 (12) United States Patent (10) Patent No.: US 9.447,114 B2 Chenard et al. (45) Date of Patent: Sep. 20, 2016 (54) THIENO- AND 2015,0111038 A1* 4, 2015 Kadam ................ CO7D 495/04 FURO2,3-DIPYRIMIDINE-2,41H,3H-DIONE 2015,0190366 A1* 7, 2015 Hous Agik ; : DERVATIVES OuSley ............... 5.14?6.5 2016/0046624 A1 2/2016 Chenard .............. CO7D 471/04 (71) Applicant: Hydra Biosciences, Inc., Cambridge, 514,264.1 MA (US) FOREIGN PATENT DOCUMENTS (72) Inventors: Bertrand L. Chenard, Waterford, CT (US); Randall J. Gallaschun, Lebanon, JP EP 0640606 A1 * 3, 1995 ........... A61K 31.505 WO WO O2O64572 A1 * 8, 2002 ... A64K 31,517 CT (US) WO WO-2004O28634 A1 4/2004 WO WO-2008070529 A2 6, 2008 (73) Assignee: Hydra Biosciences, Inc., Cambridge, WO WO-2010017368 A2 2, 2010 MA (US) OTHER PUBLICATIONS (*) Notice: Subject to any disclaimer, the term of this CAS Registry No. 606122-61-6 (Entered STN: Oct. 17, 2003).* patent is extended or adjusted under 35 CAS Registry No. 1497903-60-2 (Entered STN: Dec. 18, 2013).* U.S.C. 154(b) by 0 days. CAS Registry Nos. (Indexed 2012).* CAS Registry Nos. (Indexed 2006).* (21) Appl. No.: 14/822,018 C. Hong et al., 138 Brain, 3030-3047 (2015).* K.D. Phelan et al., 83 Molecular Pharmacology, 429–438 (2013).* (22) Filed: Aug. 10, 2015 M. Raychaudhuri et al., 2011 International Journal of Alzheimer's Disease, 1-5 (2011).* (65) Prior Publication Data J. Richter et al., 171 British Journal of Pharmacology, 158-170 (2014).* US 2016/OO398.41 A1 Feb.
    [Show full text]